Luisa Hector

are there any regions where you are losing share in toxins or fillers

if you could outline your next steps with your CAR-T and your oral peptide platforms

I just wondered whether we should be worried about the lack of any subsequent deals with the administration

I wonder if you could quantify the stocking and any gross to net impact

give a little bit more color on the rationale for those particular assets going out

how the readout from ARISE impacts your levels of confidence in Alzheimer's psychosis readout

I just wanted to take your assumption for Part D redesign, if you can quantify it in 2025

just an update on cendakimab, I don't see it on the slides, but any updates on the filing plans there

Could you just update us on your latest expectations for conversion from IV to subcutaneous and the kind of pace

comment on some of the changes we're seeing within the FDA and the HHS particularly, with reference to vaccines

could you just add a bit more color around what you're targeting for cholesterol lower, whether we might need to see